Pharma News
08 Mar 2026 to 14 Mar 2026
Mar 14, 2026
Manufacturer of Ozempic and Wegovy Did Not Disclose Incidents of Strokes, Suicidal Thoughts, and Fatalities
The FDA issued a warning letter to Novo Nordisk for failing to report serious side effects, including strokes and deaths, linked to its weight-loss drugs Ozempic, Wegovy, and Saxenda. Investigations revealed systemic failures in safety data reporting. Novo must respond within 15 days or face further enforcement actions. The company is currently facing over 4,000 lawsuits related to these issues.
Mar 14, 2026
The Competition Intensifies: Novo Looks to Wegovy to Regain Dominance Over Eli Lilly
Novo Nordisk's Wegovy pill is rapidly gaining traction in the U.S. weight-loss market, with over 600,000 prescriptions issued since its launch. This comes as the company seeks to reclaim market share from Eli Lilly, whose Orforglipron is expected to receive approval soon. Wegovy's pricing strategy, starting at $149 per month, may further influence its market penetration.
Mar 14, 2026
News Update - Pharmaceuticals
Sales of antidepressant and mood-stabilising drugs in India surged to ₹3,649 crore over five years, up from ₹2,442.41 crore in 2021. The report also noted 8,634 adverse reactions amid ongoing challenges with e-pharmacy regulations, as highlighted by the government in the Lok Sabha.
Mar 14, 2026
Wegovy Encounters Challenges as Novo Nordisk Shifts Strategy and Teams Up with Hims & Hers
Novo Nordisk's Wegovy, a leading weight-loss drug, faces intensified competition from Eli Lilly's Zepbound and has seen its 2026 sales forecasts slashed. A new partnership with telehealth platform Hims & Hers aims to enhance distribution and patient access. Despite challenges, including FDA warnings and pricing pressures, Wegovy remains a key player in the obesity treatment market.
Mar 14, 2026
Telangana Drug Enforcement Authorities Confiscate 7,300 Fake Sildenafil 100 mg Tablets Valued at ...
Telangana Drug Control Officials have seized 7,300 spurious Sildenafil 100 mg tablets, branded as Dr Josh, worth ₹2.7 lakh. The counterfeit drugs were illegally shipped from Kanpur, highlighting ongoing efforts to combat the distribution of fake medicines in the region.
Mar 14, 2026
The retail prices of Jan Aushadhi medications are approximately 50% to 80% lower than...
As of December 2025, India has opened 17,990 Jan Aushadhi Kendras (JAKs) under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, with a target of 25,000 by March 2027. Jan Aushadhi medicines are 50-80% cheaper than branded counterparts, leading to significant savings for citizens. The initiative aims to enhance access to affordable healthcare across the country.
Mar 14, 2026
Key Insights on the Potential of GLP-1 Medications in Combating Addiction - cherokeephoenix.org
Recent studies suggest that GLP-1 medications, commonly used for diabetes and weight management, may also help combat addiction. These drugs, which include semaglutide and liraglutide, appear to influence brain pathways related to reward and cravings, potentially offering a new avenue for addiction treatment. Further research is needed to fully understand their effectiveness in this area.
Mar 13, 2026
Biotech stocks drop following the unsuccessful trial of a lung cancer medication - AAP News
Immutep's shares plummeted 90% to 4 cents following the failure of its lung cancer treatment drug, drastically reducing its market capitalization from over $500 million to $52 million. The company reported $99 million in cash and received a $29.9 million licensing payment from Indian drug company Dr Reddy's in January.
Mar 13, 2026
Nationwide Drug Raids Reveal Widespread Misappropriation of Abused Medications
In a recent nationwide crackdown, police and anti-drug task forces seized over 20,000 bottles and capsules of misused pharmaceutical drugs, primarily codeine-based cough syrups and narcotic tablets. The operations highlight the rampant diversion of these substances across multiple states, underscoring ongoing challenges in combating drug misuse.
Mar 13, 2026
DRI conducts a raid on an unlawful Alprazolam manufacturing facility in Andhra Pradesh, seizing 237 kg of drugs and more than 3.5 tonnes of...
The Directorate of Revenue Intelligence (DRI) has raided an illegal Alprazolam factory in Andhra Pradesh, seizing 237 kg of the drug and over 3.5 tonnes of chemicals. Two individuals have been arrested in connection with this significant operation against the illicit production of synthetic drugs.
Mar 13, 2026
Delhi High Court greenlights the sale of biosimilar nivolumab for the benefit of the public.
The Delhi High Court has approved Zydus's sale of ZRC 3276, a biosimilar of the cancer drug nivolumab, overruling a previous injunction by Justice Pushkarna. The court emphasized public interest, noting ZRC 3276 would be 70% cheaper than the original product by Bristol-Myers Squibb. The ruling allows Zydus to market the drug until the patent expires in May 2026.
Mar 13, 2026
Leading 30 pharmaceutical firms experience a 12% increase in revenue during the first three quarters.
The top 30 Indian pharmaceutical companies reported a 12% revenue growth in the first nine months of FY2025-26, despite facing financial pressures. Companies with revenues exceeding Rs. 2,500 crore are expected to see their bottom line growth remain below double digits.
Mar 13, 2026
Abbott launches its latest drug-eluting stent, the XIENCE Skypoint™, in India.
Abbott has launched its latest drug-eluting stent, XIENCE Skypoint™, in India. This advanced stent is part of the globally recognized XIENCE™ family, which utilizes everolimus as its drug component, enhancing treatment options for patients with coronary artery disease.
Mar 13, 2026
Immutep, supported by Regal, sees a 90% drop in shares following the discontinuation of its cancer drug trial - AFR
Immutep has halted clinical trials for its lung cancer therapy Efti, following recommendations from an independent committee, resulting in a market valuation loss exceeding $500 million. Major investors, including Regal Partners, are facing significant financial setbacks as the company abandons its once-promising drug.
Mar 13, 2026
Novo Nordisk Becomes a Defensive Investment Option for DACH Investors - Born2Invest
Novo Nordisk A/S, a leader in diabetes and obesity therapies, continues to show revenue growth driven by blockbuster drugs Ozempic and Wegovy. The company remains a stable investment for DACH region investors, despite challenges from competitors like Eli Lilly's Mounjaro. With a solid dividend policy and strong market position, Novo Nordisk is well-positioned for long-term growth.
Mar 13, 2026
A timeline of the patent dispute between Amgen and Sanofi regarding Repatha and Praluent.
Amgen, Sanofi, and Regeneron have ended their long-standing patent dispute over cholesterol-lowering drugs Repatha (evolocumab) and Praluent (alirocumab). The conflict, which began in 2014, saw various legal battles in the US and Europe, including significant rulings from the US Supreme Court and the Unified Patent Court. The companies have now withdrawn their lawsuits against each other.
Mar 13, 2026
Mounjaro manufacturer cautions about risks associated with counterfeit weight-loss medications - DailyMail.com
Eli Lilly has issued a warning about unsafe knockoff versions of its weight-loss drugs Mounjaro and Zepbound, which contain the active ingredient tirzepatide. The company found significant impurities in compounded versions mixed with vitamin B12, raising safety concerns. Lilly urges consumers to avoid these products, as they pose unknown risks and lack FDA oversight.
Mar 13, 2026
Companies advised against advertising GLP-1 medications - ET BrandEquity
The government has banned advertising for GLP-1 drugs due to concerns over misuse for diabetes and obesity treatment. A circular issued warns of strict regulatory actions against any promotional activities, with a detailed advisory on the drugs expected soon.
Mar 13, 2026
Generic brands are quickly moving to capitalize on the expiration of the semaglutide patent, with long-term success expected for 5-6 key players.
A survey by Pronto Consult indicates that while over 50 generic brands of semaglutide, marketed by Novo Nordisk as Wegovy, Ozempic, and Rybelsus, are expected to launch in India, only 5 to 6 will likely remain popular among doctors after a year. Key factors influencing prescription retention include side effect management and availability, rather than just price.
Mar 12, 2026
Could Changes in Policy Boost Demand for Eli Lilly's GLP-1 Medications? - TradingView
Eli Lilly (LLY) continues to dominate the obesity market with its GLP-1 drugs, Mounjaro and Zepbound, which generated $36.5 billion in sales in 2025. The company plans to launch orforglipron, an oral GLP-1 therapy, in 2026. Expanded Medicare coverage for these therapies is expected to boost demand, despite competition from Novo Nordisk (NVO) and emerging biotech firms.
Mar 12, 2026
DCGI instructs pharmaceutical companies to halt advertising campaigns promoting GLP-1 for obesity awareness - Drugscontrol
The Central Drugs Standard Control Organisation (CDSCO) has instructed drugmakers to halt advertising campaigns for glucagon-like peptide-1 (GLP-1) agonist drugs aimed at obesity management. This directive affects all companies with marketing authorization for these medications.
Mar 12, 2026
SciSparc's patent focuses on obesity and fatty liver disease | SPRC Stock Update
SciSparc Ltd. announced a collaboration with NeuroThera Labs and Clearmind Medicine, resulting in the publication of an international patent for a novel therapy targeting weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD). The combination of 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) aims to provide a safer alternative to GLP-1 agonists, addressing global health challenges of obesity and MASLD.
Mar 12, 2026
Colombia Set to Manufacture Cancer Medications for the First Time - ColombiaOne.com
Colombia is set to produce cancer drugs domestically for the first time, focusing on a biosimilar monoclonal antibody to treat various cancers. This multimillion-dollar public investment aims to reduce reliance on imports and lower treatment costs. The initiative, backed by the Ministry of Health, seeks to enhance the country's pharmaceutical capabilities and improve access to essential therapies for cancer patients.
Mar 12, 2026
Amgen and Sanofi conclude their significant dispute regarding Praluent and Repatha - JUVE Patent
Amgen, Sanofi, and Regeneron have agreed to end their long-standing patent dispute over cholesterol-lowering drugs Repatha (evolocumab) and Praluent. The companies have mutually withdrawn lawsuits related to key patents at the European Patent Office, surprising many given the intensity of the conflict since 2014. Details of the settlement remain undisclosed.
Mar 12, 2026
CDSCO Takes Action Against Surrogate Advertising for Weight-Loss Medications: Restrictions on GLP-1 'Awareness' Campaigns
India's drug regulator, CDSCO, has banned all promotional activities for GLP-1 receptor agonist drugs, including Ozempic, ahead of its patent expiration in March 2026. The advisory targets surrogate advertising disguised as disease awareness campaigns, emphasizing that such practices will be treated as regulatory violations. Companies must also submit risk management plans to ensure safety monitoring.
Mar 12, 2026
Study Reveals Wegovy (Semaglutide) Can Increase Risk of Sudden Vision Loss by Five Times, Particularly in Men
A recent study found that Semaglutide, particularly in its Wegovy formulation, is significantly linked to an increased risk of eye stroke, with Ozempic also showing a notable association. The research indicates that men are three times more likely to be affected than women.
Mar 12, 2026
Surge in weight-loss medications in India: With patent expiration, generic versions of Ozempic and Wegovy injections could be priced at ...
The patent for semaglutide, a popular diabetes and weight loss drug, expires on March 20, allowing nearly 50 generic brands to enter the market. Companies like Dr Reddy’s, Zydus, and Cipla will offer generics at significantly lower prices, potentially reducing costs to Rs 3,000-4,000 monthly. This shift is expected to increase access to GLP-1 therapies in India.
Mar 12, 2026
New Weight Loss Medications Provide Significant Results - NYC Today
A new class of drugs based on glucagon-like peptide-1 (GLP-1), including semaglutide and tirzepatide, shows promise in obesity treatment, with patients losing 15-30% of their weight in trials. Despite their effectiveness, high costs and potential side effects raise concerns. Patents for these medications may expire between 2026 and 2030, potentially leading to cheaper generics.
Mar 12, 2026
Central Drugs Standard Control Organisation (CDSCO) Prohibits Advertising of Weight-Loss Medications
India's Central Drugs Standard Control Organisation (CDSCO) has prohibited pharmaceutical companies from promoting GLP-1 obesity drugs, including Eli Lilly's Mounjaro and Novo Nordisk's Ozempic, through awareness campaigns. The advisory warns that any indirect advertising will be treated as a violation, amid rising demand for these therapies in a market expected to see increased competition following Ozempic's patent expiry.
Mar 12, 2026
Study indicates that medications similar to Ozempic could be produced at a lower cost - Africa.com
A new study reveals that weight-loss drugs Ozempic and Wegovy, containing semaglutide, could be produced for as little as $3 per month, significantly lower than current prices. This could enhance global access to obesity and diabetes treatments, especially in lower-income countries. However, experts warn that medication alone won't address the obesity crisis, highlighting the importance of broader socio-economic factors.
Mar 12, 2026
Regulatory authorities in India issue a warning regarding aggressive marketing of weight-loss medications.
India's Central Drugs Standard Control Organisation (CDSCO) has issued a warning against direct or indirect advertising of prescription-only obesity drugs like Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic. Concerns arise over public messaging potentially promoting misuse for cosmetic weight loss rather than medical need. The advisory emphasizes the importance of comprehensive obesity management beyond pharmacological solutions.
Mar 12, 2026
Lilly Raises Alarm Over 'Worrisome' Contaminants in Compounded Tirzepatide - BioSpace
Eli Lilly has issued a warning about safety risks associated with compounded versions of its weight-loss and diabetes drug, tirzepatide. The company highlighted concerns over impurities formed when tirzepatide is mixed with vitamin B12, which may affect the drug's efficacy and safety. Lilly has been actively combating the compounding of its drugs, emphasizing the risks of untested formulations.
Mar 12, 2026
Groundbreaking Medications, Female Innovators, and the Created Patient: A Story of Intellectual Property...
Novo Nordisk's GLP-1A drugs, including Ozempic, Rybelsus, and Wegovy, have seen significant market success, generating over $20 billion in revenue in 2024. However, shortages have arisen due to high demand and manufacturing constraints. The company faces scrutiny for marketing practices, including unlawful advertising in Spain and the UK, leading to a two-year suspension by the ABPI.
Mar 12, 2026
Eli Lilly raises concerns about safety hazards linked to compounded obesity medications following the discovery of impurities.
Eli Lilly (LLY) has issued a warning regarding safety risks linked to compounded tirzepatide mixed with vitamin B12. Testing revealed significant levels of an impurity resulting from a chemical reaction between the two substances, raising concerns about the safety of these compounded products.
Mar 12, 2026
Generics accuse GSK of engaging in a "divisional strategy" following the revocation of EPO - JUVE Patent
GlaxoSmithKline's dosing patent EP 2 400 950 for vilanterol, used in respiratory treatments, has been revoked by the EPO after GSK withdrew auxiliary applications. The patent's validity was challenged by eight opponents, including Sandoz and Teva, amid accusations of strategic divisional applications to extend patent protection. GSK's respiratory products generated £4.5 billion globally in 2025.
Mar 12, 2026
Could Bristol Myers' Extensive Pipeline Be Crucial for Future Expansion? - TradingView
Bristol Myers Squibb (BMY) is advancing its pipeline with promising candidates like milvexian, admilparant, and mezigdomide, expecting key data by 2026. Recent positive results from the SUCCESSOR-2 study for mezigdomide bolster its CELMoD program. BMY faces competition from Merck's Keytruda and Pfizer's oncology portfolio, while its stock trades at a discount compared to the industry.
Mar 11, 2026
Affordable weight-loss medications become available | The Jerusalem Post
A wave of patent expirations for semaglutide, an essential medicine for diabetes and obesity, will soon allow generic versions in major markets, including Brazil, China, and India. Vimy Pharma plans to file for a generic version in Canada, where demand is high. The potential market is significant, with over one billion people affected by obesity globally.
Mar 11, 2026
In FY25, the export of active pharmaceutical ingredients reached ₹41,500 crore, exceeding the value of imports.
India's exports of active pharmaceutical ingredients reached ₹41,500 crore in FY25, surpassing imports of ₹39,215 crore, according to Chemicals and Fertilizers Minister J P Nadda. This marks a significant achievement for the country's pharmaceutical sector.
Mar 11, 2026
An Authentic Complaint Regarding JAKS - Pharmabiz.com
The Tamil Nadu Chemists and Druggists Association has filed a complaint with the Pharmaceuticals and Medical Devices Bureau of India, alleging Jan Aushadi Kendras are illegally sourcing patented and generic drugs outside authorized channels, violating PMBJP guidelines. Concerns also include multiple licenses held by individuals, undermining the scheme's goal of providing affordable medicines. The government is urged to address these unethical practices.
Mar 11, 2026
ATS Disrupts Drug Trafficking Operation: 22 Kg of Etomidate Confiscated, Two Individuals Arrested, One Being Nikunj
The Gujarat Anti-Terrorism Squad (ATS) has dismantled an international drug export racket, seizing 22 kg of the anesthetic drug etomidate. Two individuals, including Surat businessman Nikunj Gadhiya, were arrested in connection with the illegal operation.
Mar 11, 2026
Hims & Hers Welcomes Former Lilly Communications Executive - TradingView
Hims & Hers Health has appointed Kathryn Beiser, former chief communications officer at Eli Lilly, as its new chief communications officer. Beiser, who has extensive experience in corporate communications, will help reshape the company's strategy around weight loss medications. CEO Andrew Dudum praised her expertise as she begins collaborating with the leadership team.
Mar 11, 2026
Government and Pharmaceutical Sector at Odds Over Reforms in Generic Drug Pricing
The South Korean government and the pharmaceutical industry are in conflict over proposed drug price reforms aimed at reducing the 27 trillion won pharmaceutical expenditure. While the government seeks to lower prices, industry leaders warn it could harm R&D investments. Experts suggest reforms like mandatory ingredient prescribing and reference pricing to enhance competition and patient access to innovative drugs.
Mar 11, 2026
Health ministry states that weight loss drug generics can only be sold with a doctor's prescription before they become widely available.
The Central Drugs Standard Control Organisation (CDSCO) has issued an advisory regarding the promotion of GLP-1 drug semaglutide, warning that it should only be sold with a prescription. The advisory cautions against misleading promotional activities by pharmaceutical companies, including disease awareness campaigns, which may exaggerate efficacy or downplay lifestyle changes.
Mar 11, 2026
NHS approves new groundbreaking menopause medication, making it available to 500,000 women.
The NHS has approved fezolinetant, branded as Veoza, for treating menopause hot flushes in women who cannot or prefer not to use hormone replacement therapy (HRT). This non-hormonal medication, which blocks nerve signals causing symptoms, is expected to benefit around 500,000 women. Experts highlight its importance as a new treatment option for managing menopause symptoms.
Mar 11, 2026
Keytruda and Padcev may form a formidable duo in the fight against cancer | PharmaVoice
Merck & Co.'s Keytruda and Pfizer/Astellas Pharma's Padcev have shown significant promise in treating muscle-invasive bladder cancer, nearly halving the risk of tumor recurrence compared to chemotherapy. With two FDA approvals, the combination therapy is now being explored for other cancers, targeting nectin-4 positive tumors. However, challenges remain in expanding its use and ensuring patient benefit.
Mar 11, 2026
Delaware greenlights $200 copayment for weight-loss medications and introduces new premiums for state workers.
Delaware state employees will face a significant increase in copays for GLP-1 drugs, rising nearly seven-fold next year. However, this change will not affect those using the medications for diabetes treatment.
Mar 11, 2026
Curatis and Neupharma reveal exclusive licensing deal for development and ... - Markets data
Curatis Holding AG and Neupharma have entered an exclusive licensing agreement to develop corticorelin (C-PTBE-01) for treating peritumoral brain edema in Japan. The deal includes up to CHF 83.5 million in payments and 20% royalties on sales. Corticorelin aims to reduce steroid use and its side effects, with a global market potential exceeding USD 1 billion.
Mar 11, 2026
FACT SHEET: Trump Visits Cincinnati to Discuss Drug Price Reductions Following Support for...
Donald Trump's recent visit to Ohio has been criticized for failing to address rising prescription drug costs, benefiting big pharmaceutical companies instead. His administration's actions, including tax breaks for drugmakers and undermining Medicare negotiations, have reportedly led to significant profits for companies like Merck (Keytruda) and Bristol-Myers Squibb (Opdivo), while patients struggle to afford medications.
Mar 11, 2026
How GLP-1 Medications Impact Men and Women in Distinct Ways - Neuroscience News
A groundbreaking study has created the first sex-specific atlas of GLP-1 expression in the brain, revealing significant differences between males and females. Researchers found that GLP-1 density is higher in females, correlating with greater weight loss on drugs like semaglutide (Wegovy/Ozempic). The findings suggest potential for GLP-1 analogs in treating addiction, depression, and Alzheimer’s disease.
Mar 11, 2026
FDA issues warning to Novo Nordisk for not reporting fatalities and negative side effects.
The FDA has issued a warning letter to Novo Nordisk A/S (NYSE:NVO) for "serious violations" related to postmarketing adverse drug experience (PADE) reporting. This marks another regulatory action against the company in the past six months, highlighting ongoing safety and marketing issues.
Mar 11, 2026
Expiration of patent for essential Wegovy component may result in $3 generic versions - BenefitsPRO
Researchers suggest that if semaglutide proves effective and safe for long-term obesity management, lower prices through generic access could facilitate earlier intervention, enhance primary care integration, and shift focus from treating advanced metabolic complications to preventing long-term health issues.
Mar 11, 2026
India Prohibits Advertising for GLP-1 Medications Before Patent Expiration | Whalesbook
India's drug regulator has banned all advertising for GLP-1 drugs, including Novo Nordisk's semaglutide, to prevent misuse and misleading claims. This ban coincides with the upcoming patent expirations, expected to lead to a surge in generic versions and a significant market shift. Companies like Eli Lilly may also face challenges as competition intensifies in the rapidly growing GLP-1 market.
Mar 11, 2026
Mumbai Sessions Court Provides Relief to Amazon Executives in Case Involving Sale of Abortion Pills
The Mumbai Sessions Court has granted relief to directors of Amazon Seller Services in a case concerning the sale of abortion pills, quashing a previous magistrate's order for criminal proceedings. This decision highlights the challenges faced by e-commerce companies under India's Drug and Cosmetics Act 1940.
Mar 11, 2026
The Role of Pharmaceuticals in Patent Legislation: A Historical Overview, Key Changes, and Significant Clauses
India's Patents Act 1970 governs pharmaceutical patents, balancing innovation and public health. Key amendments, especially in 2005, allowed product patents, enhancing research investment but raising concerns over drug pricing. Provisions like Section 3(d) and compulsory licensing ensure access to affordable medicines. India's legal framework supports generic drug production, maintaining its role as a global supplier of low-cost medications.
Mar 11, 2026
NeuroThera Labs Reveals Release of Global Patent in Partnership ... - TradingView
NeuroThera Labs Inc. has published an international patent application for a novel combination therapy using 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). This collaboration with Clearmind Medicine Inc. aims to provide a safer, non-hallucinogenic alternative to GLP-1 agonists, addressing a growing market projected to reach $226 billion by 2035.
Mar 11, 2026
#novonordisk #semaglutide #generic #patentexpiration #diabetes #weightlossmedications ... - LinkedIn
Vikrant Shrotriya, MD of Novo Nordisk India, discussed the implications of Semaglutide's patent expiry at the CNBC-TV18 Weight Loss Drugs Townhall. He emphasized the need for serious players to enter the market post-expiry to adequately serve the diabetic population, as a few companies alone cannot meet the demand. #NovoNordisk #Semaglutide #PatentExpiry #Diabetes
Mar 11, 2026
KDventures' portfolio firm AnaCardio has secured extended intellectual property protection for AC01, lasting into the 2040s.
KDventures AB announced that its portfolio company, AnaCardio, has received US patent approval for AC01, a treatment for heart failure with reduced ejection fraction (HFrEF). The patent extends IP protection until June 2, 2042, enhancing AC01's commercial potential and clinical development prospects. KDventures holds a 10% stake in AnaCardio.
Mar 11, 2026
A Comprehensive Guide to China's Patent Term Extension (PTE) - Lexology
China's Patent Term Extension (PTE) provision, effective June 1, 2021, allows pharmaceutical invention patents to extend their term by up to five years post-marketing authorization. This initiative, part of the Fourth Amendment to the Chinese Patent Law, aims to enhance drug innovation by compensating for lengthy approval processes, aligning China's patent framework with international standards.
Mar 11, 2026
The 2026 Expiration of GLP-1 Patents: Generic Drugs, International Rivalry, and the $100 Billion Merger and Acquisition Battle
The expiration of patents for GLP-1 drugs, particularly liraglutide from Novo Nordisk, is set to transform the obesity treatment market, introducing generics and intensifying competition. Companies like Teva, Cipla, and Biocon are launching generic versions, potentially reducing costs by up to 70%. Meanwhile, semaglutide remains protected in Western markets, but is facing emerging competition in regions like Brazil and Russia.
Mar 10, 2026
Supreme Court to Review Case on Induced Infringement Related to "Skinny Label" Issue | JD Supra
The U.S. Supreme Court will hear Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., addressing "induced infringement" related to generic drug labeling. The case involves Hikma's generic Vascepa® (icosapent ethyl) and its marketing practices. The ruling could impact how generic manufacturers communicate about their products, potentially altering the balance established by the Hatch-Waxman Act.
Mar 10, 2026
Novo Nordisk reaches agreement with Hims to market Wegovy and Ozempic, withdraws lawsuit.
Hims & Hers Health will now sell FDA-approved Wegovy and Ozempic at Novo Nordisk's self-pay prices, ending a legal dispute. The partnership aims to provide affordable options amid rising competition from Eli Lilly. Hims will cease advertising compounded GLP-1 drugs, focusing on branded treatments. Novo has withdrawn its lawsuit but may refile in the future.
Mar 10, 2026
Viking Aims to Progress VK2735 Oral Medication | Intellectia.AI
Wall Street analysts are optimistic about Viking Therapeutics (VKTX), with 12 Buy ratings and a forecasted price increase. Morgan Stanley analyst Michael Ulz downgraded the price target from $102 to $99 while maintaining an Overweight rating. Canaccord initiated coverage with a Buy rating and a $106 target. Viking is developing therapies for metabolic disorders, including VK2735 and VK2809.
Mar 10, 2026
Impending Price Competition for Semaglutide in India: Over 50 Generic Manufacturers Compete to Enhance Patient Access
By March 2026, India will introduce over 50 generic semaglutide brands, reducing prices by up to 85%, enhancing access for 100 million Type-2 diabetics. Companies like Dr. Reddy's Laboratories, Sun Pharma, and Cipla are focusing on patient support and digital tools to foster loyalty amid increased competition. The market shift emphasizes the importance of patient experience over pricing alone.
Mar 10, 2026
Hims & Hers and Novo Nordisk Come Together Again for GLP-1 Agreement Following Recent Legal Dispute - Athletech News
Hims & Hers shares surged 54% after announcing a renewed partnership with Novo Nordisk to offer FDA-approved weight-loss drugs Wegovy and Ozempic. This agreement follows the dismissal of Novo's patent infringement lawsuit against Hims. The collaboration aims to enhance distribution of GLP-1 medications, marking a significant shift in their relationship amid the competitive weight-loss drug market.
Mar 10, 2026
Xenon achieves success in Phase 3 trials for its epilepsy medication, raising expectations for a major market debut.
Xenon Pharmaceuticals reported that its lead drug significantly reduced seizure frequency in a Phase 3 epilepsy study, bolstering the company's plans to seek FDA approval.
Mar 10, 2026
Novo's obesity medication achieves a 19.7% weight reduction in clinical trial conducted in China - Longevity.Technology
Novo Nordisk and United Laboratories' UBT251, a next-gen triple-agonist obesity drug, achieved an impressive 19.7% average weight loss in a mid-stage trial in China, compared to 2% in the placebo group. The trial also showed improvements in various health metrics. The companies are optimistic about UBT251's potential, with further global trials planned for 2027.
Mar 10, 2026
AbbVie Projects Strong Single-Digit Growth Until 2030 - Chicago Today
At the Leerink Global Healthcare Conference, AbbVie's CFO Scott Reents projected strong growth for the company, aiming for $67 billion in revenue by 2026. He emphasized AbbVie's derisked portfolio, including the blockbuster immunology drug SKYRIZI, as key to achieving high single-digit growth through the 2020s and into the 2030s, ensuring stability in a competitive market.
Mar 10, 2026
Semaglutide May Be Priced as Low as $28 by Year’s End - ZME Science
Semaglutide, initially developed for type 2 diabetes, has gained popularity for its weight loss effects, with 1 in 8 Americans using it. Currently priced at $1,000 per box, a study predicts generic versions could be available by April 2026, potentially reducing costs to as low as $28 per year. This could significantly impact global obesity and diabetes treatment.
Mar 10, 2026
Examination of High-Yield Pharmaceutical Stocks | Intellectia.AI
Argus has upgraded Pfizer to a Buy rating from Hold, setting a price target of $35. The firm is optimistic about Pfizer's GLP-1 pipeline and its strong oncology and hematology programs, expressing increased confidence in the company's growth potential beyond 2028 due to accelerated R&D and successful product launches.
Mar 10, 2026
Telehealth and the Weight Loss Surge: The Impact of Hims & Hers' Partnership with Wegovy
Hims & Hers Health shares surged following news of a potential partnership with Novo Nordisk to offer the weight-loss drug Wegovy, which contains semaglutide. This collaboration could enhance access to Wegovy through telehealth services, reflecting a shift in healthcare delivery. The growing demand for GLP-1 medications highlights the evolving landscape of obesity treatment and digital healthcare integration.
Mar 10, 2026
Hims Collaborates with Novo to Compete in the Weight Loss Prescription Market - The Daily Upside
Novo Nordisk has partnered with Hims & Hers to offer official versions of its GLP-1 drugs, Ozempic and Wegovy, following a lawsuit over Hims selling knockoffs. This collaboration comes as Novo's weight-loss pill Wegovy has gained significant traction, with 600,000 prescriptions. Hims' shares surged 47% post-announcement, while Novo has reduced drug prices amid increased competition.
Mar 10, 2026
Research on mouse brains uncovers reasons why popular weight-loss medications might have varying effects in...
Researchers at the Icahn School of Medicine at Mount Sinai have created a comprehensive sex-specific atlas of GLP-1 expression in the mouse brain, revealing significant differences between males and females. This study, which includes drugs like semaglutide, liraglutide, and lixisenatide, highlights the implications for obesity, diabetes, and potential psychiatric applications, emphasizing the need for tailored GLP-1 therapies.
Mar 10, 2026
Novo Nordisk and Hims & Hers mend their relationship - Morning Brew
Novo Nordisk and Hims & Hers have resolved their legal dispute and will collaborate to sell Ozempic and Wegovy online. Hims will offer both oral and injectable forms of these medications, with shares surging 40%. Novo had previously sued Hims for patent violations but will drop the lawsuit while retaining the option to refile.
Mar 10, 2026
Novo Nordisk agreement allows Hims to market Wegovy and Ozempic, leading to lawsuit dismissal - USA Today
Novo Nordisk has partnered with Hims & Hers Health to sell its weight-loss drugs, Wegovy and Ozempic, through the telehealth platform, resolving a legal dispute. Hims will offer FDA-approved products at Novo's self-pay prices, ceasing the advertisement of compounded versions. This move follows FDA warnings against misleading promotions of such drugs, as competition in the weight-loss market intensifies.
Mar 10, 2026
Novo Nordisk withdraws patent litigation against Hims & Hers regarding their collaboration on a weight loss medication.
Novo Nordisk has dropped its lawsuit against Hims after the companies reached a deal to sell Wegovy and Ozempic through Hims' platform. Hims will cease advertising compounded GLP-1 drugs and will offer both oral and injectable versions of Wegovy. Following the announcement, Hims' shares surged over 36%, while Novo Nordisk's shares rose 1.8%.
Mar 10, 2026
Clearmind Medicine Reveals Release of Global Patent for Innovative Treatment ... - BioSpace
Clearmind Medicine Inc. has announced an international patent application for a novel therapy combining 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). This non-hallucinogenic treatment aims to provide a safer alternative to GLP-1 agonists, addressing a growing market projected to exceed $200 billion by 2035.
Mar 10, 2026
Alligator Bioscience Enhances IP Safeguards for Its Bispecific Antibody Technology
Alligator Bioscience (STO:ATORX) has received a patent from the USPTO for its bispecific antibody format, enhancing its immuno-oncology drug development. This patent supports the creation of next-generation therapies targeting immune modulators and tumor antigens. CEO Søren Bregenholt emphasized its strategic importance, particularly in relation to their lead candidate, mitazalimab, which is advancing to Phase 3 trials.
Mar 10, 2026
Clearmind Medicine submits PCT application for MEAI-PEA treatment for obesity | CMND Stock Update
Clearmind Medicine Inc. has announced the publication of an international patent for a novel therapy combining 5-methoxy-2-aminoindane (MEAI) and Palmitoylethanolamide (PEA) to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). This non-hallucinogenic treatment aims to provide a safer alternative to GLP-1 agonists, addressing a growing market projected to exceed $200 billion by 2035.
Mar 10, 2026
Novo Nordisk withdraws its patent lawsuit | The Arkansas Democrat-Gazette
Novo Nordisk has dropped its patent infringement lawsuit against Hims & Hers after the companies reached an agreement allowing Hims to sell its branded weight loss medications, including Wegovy and Ozempic. Hims will cease advertising compounded GLP-1 drugs. Following the announcement, Hims & Hers shares surged over 36%, while Novo Nordisk's shares rose 1.8%.
Mar 10, 2026
Immunic obtains European patent for its multiple sclerosis treatment candidate, vidofludimus calcium.
Immunic Inc has secured a European patent for its multiple sclerosis drug candidate, vidofludimus calcium, extending market protection until 2038. The patent covers dosing regimens and various forms of the compound. Currently in phase 3 trials, vidofludimus calcium shows promise for chronic inflammatory diseases, with top-line data expected by late 2026.
Mar 10, 2026
Alligator Bioscience enhances its intellectual property safeguards for its bispecific antibody technology.
Alligator Bioscience has received a patent from the USPTO for its proprietary bispecific antibody format, enhancing its immuno-oncology drug development. This patent supports the company's innovative antibody architecture, including the RUBY™ format. CEO Søren Bregenholt emphasized its strategic value, particularly for their lead drug candidate, mitazalimab, which is advancing to Phase 3 trials for pancreatic cancer.
Mar 10, 2026
Taiwan's rulings on generic drug indication exemptions address patent violations and slim labeling.
Taiwan's courts have affirmed the legality of the skinny-label strategy for generic drugs, allowing manufacturers to exclude certain indications from marketing certificates to mitigate patent infringement risks. Recent rulings clarify that while off-label use by physicians may not directly implicate generic manufacturers, future evidence of foreseeability could alter liability assessments. The decisions emphasize the need for clear distinctions between labeled and patented indications.
Mar 9, 2026
FDA releases draft guidance on three-year exclusivity, outlining the criteria needed to secure it and...
On March 3, 2026, the FDA released draft guidance on "New Clinical Investigation Exclusivity" for drug products, clarifying eligibility criteria and decision-making processes for 3-year exclusivity. The guidance addresses common questions and outlines requirements for new clinical investigations essential for drug approval. Stakeholders can submit comments by May 4, 2026.
Mar 9, 2026
Section 101 Excludes Claims Related to Utilizing Biomarkers for Identifying Potentially Harmful Drugs ... - Mondaq
A U.S. court ruled that Nextcea Inc.'s patent (U.S. Patent 8,313,949) for methods testing drug-induced phospholipidosis (DIP) is ineligible for patent protection. The court found the claims merely describe natural phenomena without an inventive concept, echoing previous rulings on diagnostic method patents. This decision highlights ongoing challenges in patenting methods related to biomarkers and diseases.
Mar 9, 2026
Delhi High Court affirms decision permitting Dr. Reddy's to produce Ozempic-like medication for export purposes.
The Delhi High Court upheld an order allowing Dr Reddy's to manufacture Semaglutide, a diabetes management and weight-loss drug, for export to countries without patent protection from Novo Nordisk. This decision enables Dr Reddy's to produce the drug under brand names like Ozempic.
Mar 9, 2026
Police Operation Sheds Light on Drug Diversion Issues and Supply Chain Shortcomings in India
Police in India have conducted crackdowns revealing a significant drug diversion crisis, particularly involving codeine-laced cough syrups and narcotic pills. The operations, which took place across several states including Bihar and Uttar Pradesh, highlight critical gaps in the pharmaceutical supply chain and the ongoing issue of illegal drug trade.
Mar 9, 2026
Delhi High Court Rejects Novo Nordisk's Request to Halt Dr. Reddy's Exports of Essential Ozempic Component
The Delhi High Court has ruled in favor of Dr Reddy's Laboratories Ltd. in its legal battle with Novo Nordisk over semaglutide, a key ingredient in diabetes and weight management drugs like Ozempic and Wegovy. This decision allows Dr Reddy's to manufacture and export semaglutide to countries not covered by Novo's patent, which expires in March 2026.
Mar 9, 2026
Patent Approaches for Digital Twins in Life Sciences: Focus on Eligibility, Enforcement, and Structure
Digital twin technologies are transforming the life sciences sector, enhancing drug development and medical device performance through AI and machine learning. As patent filings surge, companies must navigate eligibility challenges under 35 U.S.C. § 101 and ensure robust claim structures for enforceability. Strategic patent drafting is essential to protect innovations in this rapidly evolving field.
Mar 9, 2026
Novo Nordisk concludes legal actions against Hims & Hers - CNBC
Hims & Hers has reached an agreement with Novo Nordisk to sell injectable and oral semaglutide, branded as Ozempic and Wegovy, at competitive prices, ceasing the advertisement of compounded GLP-1 drugs. Novo has dropped its patent infringement lawsuit against Hims, leading to a 40% surge in Hims' shares. FDA Commissioner Marty Makary welcomed the deal, emphasizing patient safety.
Mar 9, 2026
Hims & Hers Health and Novo Nordisk Resolve Legal Dispute Regarding Weight Loss Drugs, Begin ...
Novo Nordisk has dropped its patent infringement lawsuit against Hims & Hers after the companies reached an agreement allowing Hims to sell its branded weight loss medications, Wegovy and Ozempic. Hims will cease advertising compounded GLP-1 drugs. Following the announcement, Hims & Hers shares surged over 36%, while Novo Nordisk shares rose 1.8%.
Mar 9, 2026
Novo Nordisk and Hims settle contentious disagreement regarding Wegovy sales - STAT News
Novo Nordisk and Hims & Hers have settled their dispute over Hims' sale of compounded versions of Novo's obesity drug Wegovy. Novo has dropped its patent infringement lawsuit, while Hims will stop advertising compounded GLP-1 products and offer Wegovy injections and pills at cash prices. The impact on compounded product prescriptions remains uncertain.
Mar 9, 2026
Novo Nordisk reaches agreement with Hims to market Wegovy and Ozempic, withdraws lawsuit | WKZO
Novo Nordisk has partnered with Hims & Hers Health to sell its weight-loss drugs, Wegovy and Ozempic, through the telehealth platform, resolving a legal dispute. Hims will offer FDA-approved products at Novo's self-pay prices, ceasing the advertisement of compounded versions. This move comes amid rising competition and regulatory scrutiny in the weight-loss drug market.
Mar 9, 2026
Hims shares surge 50% following Novo Nordisk's lawsuit dismissal and agreement - TradingView
Novo Nordisk has dropped its patent infringement lawsuit against telehealth provider Hims & Hers, allowing the distribution of its semaglutide drugs, including Ozempic and Wegovy, through Hims' platform. This agreement ends a dispute over copycat versions of the obesity drug and highlights the growing collaboration between drugmakers and online health platforms. Hims' shares surged 50% following the news.
Mar 9, 2026
Novo Nordisk Concludes Legal Dispute and Partners with Hims & Hers to Market Semaglutide
Novo Nordisk has dropped its patent infringement lawsuit against Hims & Hers after the companies reached an agreement allowing Hims to sell branded semaglutide (Ozempic, Wegovy) products. Hims will offer oral and injectable semaglutide for weight loss and diabetes, while ceasing advertisements for compounded GLP-1 drugs. Novo Nordisk retains the right to refile the lawsuit in the future.
Mar 9, 2026
Hims & Hers surges following possible agreement with Novo Nordisk - TradingView
Shares of Hims & Hers Health (HIMS) surged 44% in premarket trading following reports of a potential partnership with Novo Nordisk (NVO) to distribute its weight-loss drugs. This agreement could be announced soon, despite previous conflicts over Hims & Hers' lower-cost compounded versions of semaglutide and regulatory issues surrounding Wegovy.
Mar 9, 2026
Hanmi Pharmaceutical Suspends Plans to Alter Ingredients for Popular Medication Rosuzet
Hanmi Pharmaceutical has suspended its plan to change the active pharmaceutical ingredient supplier for its dyslipidemia treatment, Rosuzet, following controversy over proposed lower-cost imports from China. CEO Park Jae-hyun emphasized the importance of using verified materials, prioritizing public health over cost-cutting. The Korean Pharmaceutical Association supported this decision, stressing the need for scientific verification in ingredient changes.
Mar 9, 2026
Delhi High Court denies Novo Nordisk's request to prevent Dr. Reddy's from producing a drug similar to Ozempic.
The Delhi High Court has allowed Dr Reddy’s Laboratories (DRL) to manufacture and export semaglutide, marketed as Ozempic by Novo Nordisk, as the patent is set to expire in two weeks. The court upheld a previous ruling, noting DRL's credible challenge to the patent's validity, emphasizing the urgency of the case given the impending expiration.
Mar 9, 2026
With rising demand, the chemists' association urges its members to market GLP-1 medications for obesity and diabetes.
The All India Organisation of Chemists and Druggists (AIOCD) has directed its members to sell GLP-1 drugs, including semaglutide (Ozempic, Wegovy) from Novo Nordisk and tirzepatide (Mounjaro, Zepbound) from Eli Lilly, only with valid prescriptions. This move aims to prevent misuse as generic versions of semaglutide are set to launch in India following its patent expiration.
Mar 9, 2026
India's Struggle with Obesity: The Surge in Demand for Weight Loss Medications from Pharmaceutical Companies
India faces a growing obesity crisis, with Prime Minister Narendra Modi urging healthier lifestyles. The World Obesity Federation reports India ranks second in child obesity. Eli Lilly's Mounjaro, a GLP-1 receptor agonist, launched in 2025, has gained rapid popularity. Critics warn against the commercialization of obesity treatment, emphasizing the need for comprehensive public health solutions beyond pharmaceuticals.
Mar 9, 2026
The age of $199 imitation weight loss medications is coming to a close, which may have financial implications for patients - Yahoo
Hims & Hers has ceased advertising compounded GLP-1 drugs and will now sell name-brand medications, including Novo Nordisk's Ozempic and Wegovy, through its telehealth platform. This decision follows a lawsuit settlement with Novo Nordisk and FDA scrutiny over compounded drugs. While this transition may increase costs for patients, it aims to ensure access to FDA-approved treatments.
Mar 9, 2026
Dr. Reddy's Triumphs in Semaglutide Export Competition, Sparking Race in Generic Market | Whalesbook
The Delhi High Court has dismissed Novo Nordisk's attempt to block Dr. Reddy's Laboratories from exporting semaglutide, allowing Indian generics to enter global markets ahead of patent expirations. This ruling could lead to significant price reductions and increased access to diabetes treatments. Novo Nordisk plans to launch a new brand, Extensior, in India amid rising competition.
Mar 9, 2026
As Patents Expire, Production Costs for Weight-Loss Medications May Drop to $3 Monthly - Science Alert
Researchers indicate that semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, could cost as little as $3 per month to manufacture after losing patent protection later this month. This price drop could significantly improve access to treatment for obesity and diabetes in low and middle-income countries, where 69% of Type 2 diabetes patients reside.
Mar 9, 2026
Novo Nordisk Stock Experiences Increased Strain Following Profit Alert and Pricing Changes
Novo Nordisk has issued a profit warning following U.S. price cuts and a failed clinical trial for its combination drug CagriSema. The company is acquiring Akero Therapeutics for $5.2 billion to diversify beyond its GLP-1 drugs like Wegovy and Ozempic. Analysts have mixed views on the stock, with Deutsche Bank downgrading it and Morgan Stanley upgrading it amid significant share price declines.
Mar 9, 2026
Dr. Reddy's Triumphs in Semaglutide Export Dispute, Ignites Worldwide Generic Competition - Whalesbook
The Delhi High Court has dismissed Novo Nordisk's attempt to block Dr. Reddy's Laboratories from exporting semaglutide, paving the way for increased competition in the global market. This ruling allows Dr. Reddy's and other Indian firms to produce generics, potentially reducing prices by 30-75% and enhancing patient access to diabetes treatments. Novo Nordisk plans to launch its new brand, Extensior, in India.
Mar 9, 2026
The production cost of Ozempic's main component may be as low as $3 per month, according to NCHStats.
A new analysis suggests that semaglutide, the active ingredient in Ozempic and Wegovy, could be produced for as little as $3 per month once patent barriers fall in various countries. This could significantly improve access to the drug for obesity and type 2 diabetes treatment, currently priced around $200. However, challenges remain in ensuring affordable access and integrating it into healthcare systems.
Mar 9, 2026
Indian-American researcher Vinay Prasad resigns from his position at the FDA once more due to conflicts with the pharmaceutical industry.
Indian-American scientist Vinay Prasad has resigned from his FDA role again, following controversies regarding his efforts to tighten regulations on vaccines and new therapies. This marks his second departure from the position, highlighting ongoing clashes within the pharmaceutical sector.
Mar 9, 2026
Reasons Behind Bristol Myers Squibb's Stock Surge in February - The Globe and Mail
Bristol Myers Squibb (NYSE: BMY) reported a modest 1% revenue growth to $12.5 billion in Q4 2025, despite a 24% drop in net income. The company's growth portfolio, led by cancer drug Opdivo, rose 16% to $7.4 billion, offsetting declines in its legacy treatments like Eliquis. The FDA accepted a new drug application for iberdomide, signaling positive pipeline progress.
Mar 8, 2026
Wockhardt's Nafithromycin 400 mg could be granted a five-year exemption from price regulation.
The National Pharmaceutical Pricing Authority's Multidisciplinary Committee has recommended granting a five-year exemption from price control for Nafithromycin Tablets 400 mg, manufactured by Wockhardt Limited. This decision follows a review confirming that the formulation is covered under Patent No. 415319, granted to Wockhardt. The exemption is based on the Drugs (Prices Control) Order, 2013.
Mar 8, 2026
Chinese Biotechnology Company Lonvi Biosciences Introduces Anti-Aging Supplement Made from Grape Seeds
Lonvi Biosciences, a Shenzhen-based biotech startup, has launched its anti-aging supplement, the Lonvi PCC1 Grape Seed Complex, branded as SenoC1 - Lonvi 3 Days Pulse. The product aims to promote cellular rejuvenation and potentially extend lifespans, marking a significant step in the company's anti-aging initiatives.
Mar 8, 2026
D&D Pharmatech Secures Europe's First Bio-Secure Patent for Brain Disorder Medication
D&D Pharmatech and First Biotherapeutics have secured a European patent for their neurodegenerative disease drug, NLY02, which protects brain neurons by inhibiting the RIPK2 protein. This patent follows a similar approval in the U.S., enhancing their intellectual property framework for future global commercialization efforts. Both companies aim to leverage their collaboration for successful market entry.
Mar 8, 2026
Alteogen is enhancing its presence in the international biotechnology sector through innovative platform technology that transforms i...
Alteogen is enhancing its global bio market presence with its Hibrozyme platform, converting IV drugs to subcutaneous forms. Notably, it has developed the subcutaneous formulation of Merck's Keytruda, which has received commercialization approval in the U.S. and Europe. The company reported record sales and profits, driven by technology fees and partnerships with firms like AstraZeneca and GSK.
Mar 8, 2026
Three Businessmen from Surat Taken into Custody for Smuggling Etomidate Powder Labeled as Aloe Vera
The Gujarat Anti-Terrorist Squad arrested three Surat businessmen for allegedly smuggling etomidate, an anesthetic drug, disguised as aloe vera. The arrests occurred on March 7, 2026, during a significant operation against international drug trafficking.
